Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab + FOLFOX4 in Advanced HCC
NCT02069041Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2014
- Primary completion
- Sep 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ramucirumab in hepatocellular carcinoma (HCC), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration up To 8 Months. Started Apr 2014; status: completed.
02
Drugs
ramucirumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02069041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02069041.